Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia

Betibeglogene autotemcel (Zynteglo — Bluebird Bio), an autologous lentiviral vector cell-based gene therapy, has been approved by the FDA for one-time treatment of transfusion-dependent beta thalassemia in children and adults.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2024-09-19
DOI
https://doi.org/10.58347/tml.2024.1712c
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Virus-based gene therapy research
article

Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia

article en

Abstract

Betibeglogene autotemcel (Zynteglo — Bluebird Bio), an autologous lentiviral vector cell-based gene therapy, has been approved by the FDA for one-time treatment of transfusion-dependent beta thalassemia in children and adults.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 66(1712)
Good health and well-being
Openalex Percentile: Top 82%
Virus-based gene therapy research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2024) | TGRS Research Map | TGRS